To determine the prognostic significance of circulating tumor cells (CTCs) in patients with neuroendocrine cancer.
INTRODUCTION
Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that arise most commonly from the GI tract. Incidence is approximately five per 100,000, but because of prolonged survival in some groups, the prevalence exceeds those of pancreatic, gastric, and esophageal cancers in the United States. 1 In the past few years, there have been a number of important advances in therapy, including the approval of sunitinib 2 and everolimus 3 for well-differentiated pancreatic NETs.
Currently, tumor grade provides the best method of defining prognosis, 4,5 but this is usually based on a small biopsy sample that may not reflect the heterogeneity present in advanced tumors. 6 Furthermore, the sample may have been taken years before a treatment decision needs to be made and may not be representative of the tumor that has evolved. Additionally, there are no prospectively validated biomarkers for predicting outcome from treatment. Response to treatment is a poor surrogate for survival benefit because the best response is often stable disease, and if there is a response, it can be delayed by up to 1 year. 7, 8 Therefore, there is a pressing need to develop robust biomarkers for NETs that can inform patient management and facilitate drug development.
There has been increasing interest in circulating tumor cells (CTCs) as biomarkers since the development of technology that can detect CTCs in small volumes of blood. The CellSearch platform detects CTCs with high sensitivity, specificity, and reproducibility and is the only system approved by the US Food and Drug Administration. Large studies have reported that the number of CTCs in patients with metastatic breast cancer is an independent predictor of progression-free (PFS) and overall survival (OS), 9, 10 with similar results reported in metastatic colorectal and prostate cancers. 11, 12 The CellSearch platform requires the cellular expression of the epithelial cell adhesion molecule (EpCAM), and we recently reported that a majority of NETs have strong heterogeneous membranous expression of EpCAM and that CTCs can be detected in patients with NETs.
13 Therefore, we sought to define the prognostic relevance of CTCs in a large population of patients with NETs. To our knowledge, this is the first such report.
PATIENTS AND METHODS

Patients
This was a prospective single-institution study conducted at the Royal Free Hospital, London, United Kingdom. The study was approved by the local ethics committee, and all patients provided written informed consent. Eligible participants were age Ͼ 18 years and had histologically proven NETs and metastatic disease measurable by RECIST 1.1.
14 Patients who had undergone systemic anticancer therapy or embolization within the previous 2 months were excluded because recent treatment has been shown to affect CTC count in other tumors. 11, 15, 16 Patients receiving long-term somatostatin (SST) analogs were permitted. Data were collected on primary site, previous treatment, Male  25  54  8  4  1  92  Female  17  47  9  8  2  83  Grade  Low  17  59  6  1  0  83  Intermediate  10  36  8  7  2  63  High  15  6  3  4  1  29  Burden of liver metastases, %  Յ 25  19  48  11  4  1  83  25 to Յ 50  15  36  4  4  0  59  50 to Յ 75  3  11  2  3  1  20  Ͼ 75  5  6  0  1  1  13  Duration of diagnosis, months  Median  41  30  22  13  18  26  Range  2-166  1-134  9-287  1-67  5-22  1-287  ECOG PS  0  29  60  12  6  1  108  1  1 3  3 4  5  5  2  5 9  2  0  6  0  0  0  6  3  0  0  0  1  0  1  4  0  1  0  0  0  1  Previous treatment  Resection of primary  18  50  6  0  1  75  SST  13  59  3  3  1  79  Chemotherapy  18  10  4  6  1  39  TAE  3  13  0  2  0  18  PRRT  5  16  1  1  0  23  Interferon  3  2  0  0  0  5  Liver resection  7  10  0  0  0  17  Subsequent treatment  SST  3  26  3  2  0  34  Chemotherapy  13  5  3  7  1  29  TAE  4  10  2  1  1  18  PRRT  6  30  2  1  1  40  Interferon  0  4  0  0  0  4  Sunitinib  4  0  0  0  0  4  Surgery  0  5  2  0  0  7  RFA  1  1  0  0  0  2 Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NET, neuroendocrine tumor; PRRT, peptide receptor radionuclide therapy; RFA, radiofrequency ablation; SST, somatostatin analogue; TAE, transarterial embolization.
and Eastern Cooperative Oncology Group performance status, and grade of tumor based on Ki-67 proliferation index was recorded according to European Neuroendocrine Tumor Society guidelines. 4, 5 Baseline assessments included hepatic tumor burden from four to six slices of a computed tomography/magnetic resonance imaging scan selected at the level of greatest relative disease and categorized as Յ 25%, 25 to Յ 50%, 50% to Յ 75%, or Ͼ 75% based on the relative area of tumor to normal liver. Baseline chromogranin A (CgA) analysis was performed on plasma samples at the same time point as CTC sampling using a radioimmuno assay kit (Roche; Basel, Switzerland).
CTC Analysis
CTC enumeration was performed using the CellSearch (Veridex, Raritan, NJ) system as described previously.
13 Blood samples were collected in 10-mL CellSave tubes (Veridex), stored at room temperature, and analyzed within 96 hours according to manufacturer instructions. All evaluations were performed without knowledge of the clinical status of the patients by two independent operators (M.S.K., T.T.). Data regarding reproducibility and results from healthy controls were previously reported.
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Statistical Analysis
Previously, we demonstrated a median PFS of 9.1 months in a series of patients with NETs attending our clinic to start chemotherapy.
7 Assuming a power of at least 90% and two-sided ␣ of 0.05, a sample size of 138 would be needed to detect a hazard ratio (HR) of at least 2, corresponding to a median PFS of 6 months in the good prognosis group and 12 months in the bad prognosis group, as defined by CTC cutoff. Because we were unsure of the proportion of patients falling into each group, we increased the sample size to 168 to allow for a ratio (good prognosis to bad prognosis) as low as 0.4 or as high as 2.5 (bad prognosis to good prognosis). To define a prognostic cutoff with respect to the number of CTCs detected, we applied the internal validation method described by Altman et al 18 and divided the whole data set into a training set and validation set. Results for the first 90 patients enrolled (training set) were used to select a cutoff level of CTCs. This cutoff level was then validated with the 85 patients subsequently enrolled onto the study (validation set).
Analysis was performed using SPSS for Windows (SPSS, Chicago, IL) and GraphPad Prism (GraphPad Software, San Diego, CA), where P values Ͻ .05 were considered significant. Differences in baseline characteristics between progressors and nonprogressors were analyzed using Fisher's exact, MannWhitney, and t tests. Correlations between CTCs and continuous or ordinal clinicopathologic data were assessed using Spearman's rank test. Associations between level of CTCs and dichotomous variables were evaluated with the Mann-Whitney U test. Association between presence or absence of CTCs and clinicopathologic data was analyzed using 2 (or Fishers) or MannWhitney test. Because CgA was not normally distributed (even when transformed onto a logarithmic scale), this was analyzed in two groups: Ͼ and Ͻ 2ϫ the upper limit of normal (ULN; 120 pmol/L), consistent with previous studies. 19 Age was analyzed as a continuous variable, and HRs are presented for 10-year intervals.
PFS and OS were estimated using Kaplan-Meier methods from date of baseline sample to date of radiologic progression (RECIST 1.1) and date of death resulting from neuroendocrine cancer or last follow-up. Radiologic progression was assessed by an independent radiologist blind to study. Survival curves were compared using log-rank testing. Cox proportional hazards regression analysis was used to obtain univariate HRs for PFS or OS. Factors found to be significant on univariate analysis were included in multivariate analysis in addition to age. The study design met the REMARK (REporting recommendations for tumor MARKer prognostic studies) criteria. Table 1 . Patients had been diagnosed a median of 26 months (range, 1 to 134 months) before sampling, and at the time of analysis, the median follow-up was 12.6 months (range, 5 to 28 months).
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RESULTS
Between
CTC Count in Relation to Clinicopathologic Characteristics
Enumeration of CTCs according to primary NET is listed in Table 2 . Because of the low number of hindgut NETs, the data are not shown in the figure, but one of these three patients had CTCs (10/7.5 mL). Overall, for all 175 patients, the mean number of CTCs was 45 (standard deviation, 300); 49% had at least one CTC; 42%, Ն two; and 30%, Ն five.
For all NETs, the liver burden categories (ie, 25% to 50%, 50% to 75%, and Ͼ 75%) were combined because of the small number of patients in these categories (n ϭ 59, 20, and 13, respectively) compared with those in the Ͻ 25% category (n ϭ 83). CTC levels were higher in patients with a greater burden (Mann-Whitney P Ͻ .001). There was a weak correlation between CTC level and grade (r ϭ 0.224; P ϭ .003) and CgA (r ϭ 0.29; P Ͻ .001). However, applying presence or absence of CTCs as a dichotomous variable, there was a significant association between grade (P ϭ .036) and CTC presence and between CgA and CTC presence (P Ͻ .001). There was no association between SST therapy and presence of CTCs ( 2 P ϭ .508), nor between SST therapy and number of CTCs (Mann Whitney P ϭ .359).
Establishing Prognostic Threshold for CTCs
To establish the optimal prognostic CTC threshold, we systematically evaluated CTC number and PFS using a training set comprising 90 patients. Kaplan-Meier survival curves were plotted comparing patient groups above and below each threshold and log-rank testing performed to obtain significance levels of difference across groups. Thresholds were tested commencing at CTCs of Ն one, increasing by one CTC until 50 CTCs. Thereafter, CTC thresholds between 50 and 1,000 were tested at increments to include the next CTC count sequentially. Both HRs and difference in 1-year survival were greatest comparing groups without CTCs (CTC ϭ 0) and those with CTCs (CTC Ն one; Appendix Table A1 , online only). The same cutoff was also defined when OS was analyzed instead of PFS. Thus, a cutoff of Ն one CTC per 7.5 mL was chosen to distinguish patients with an unfavorable prognosis from patients with a favorable prognosis. The CTC threshold was tested in an 85-patient validation set. The distributions of patients above and below the cutoff level in the training and validation sets were compared with the use of Fisher's exact tests, and median PFS and median OS in the two sets were compared with nonparametric k-sample test for equality of the medians. All P values were two sided. Neither PFS nor OS was significantly different between the validation and training sets (P ϭ .32; P ϭ .56). The distribution of patients with CTC levels above the cutoff of Ն one CTC per 7.5 mL blood did not differ between the training and validation sets (P ϭ .41). The cutoff level from the training set was confirmed as separating two significantly different prognostic groups in this validation set. Kaplan-Meier curves for the training and validation sets are shown in Appendix Figure A1 (online only), and patient characteristics for the two sets are listed in Appendix Table A2 ( 
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CTCs As Prognostic Markers
Overall, 1-and 2-year OS were 79% (SE, 3) and 73% (SE, 4), and 1-and 2-year PFS were 72% (SE, 4) and 49% (SE, 6), respectively. In univariate analysis, we confirmed that grade, CgA, and tumor burden were prognostic (Table 3) . However, the highest hazard ratios for both PFS and OS were defined by CTC Ͻ one or Ն one. Kaplan-Meier survival curves of PFS and OS are shown in Figure 1 , and the results are consistent with the univariate analysis demonstrating a significant difference in outcome between those with and without CTCs. Applying multivariate analysis, CTC presence or absence remained a highly significant discriminator in terms of PFS and OS (Table 3) . Of the other factors, grade retained significance for PFS and OS, and age was significant for PFS alone. When the midgut cohort was analyzed separately, presence of CTCs was a significant prognostic factor for OS and PFS, whereas for the pancreatic cohort, there was a similar trend, but this was nonsignificant, possibly because of the smaller number in this subgroup (Appendix Tables A3 and A4 , online only).
Because grade 1 and 2 tumors constitute a large and potentially heterogeneous subgroup, we also examined the prognostic significance of CTCs within these subgroups. Applying univariate analysis, only CTC presence or absence was significant for PFS and OS among the 83 patients with grade 1 and 63 patients with grade 2 tumors (Tables 4 and 5 ).
DISCUSSION
In this study, the number of CTCs detected in patients with NETs was comparable to other tumors in which CTCs have been shown to have prognostic relevance. Overall, 42% of patients with NETs had Ն two detectable CTCs, as compared with 57% for prostate, 37% for breast, 30% for colorectal, and 20% for non-small-cell lung cancers. 17 In our study, the greatest number of patients had midgut (n ϭ 101) or pancreatic (n ϭ 42) tumors, and in these subgroups, 47% and 24%, respectively, had Ն two CTCs detected. The reason for the high detection rate may be the high expression of EpCAM, which we and others have demonstrated in NETs. 13, 21, 22 Using a training set, we found that the optimum threshold for prognostication using CTCs was Ն one. For metastatic breast, prostate, and non-small-cell lung cancers, a CTC count of Ն five has been used to define an unfavourable group, 10,12,23 whereas for colorectal cancer, Ն three has been used. 24 In early breast cancer, presence of Ն one CTC defines a poor prognostic group. 25 Applying a cutoff or three or five cells in our training set gave rise to a lower HR and difference in 1-year survival compared with a threshold of Ն one. In a study of 145 healthy female volunteers, eight patients (5.5%) were found to have Ն one, whereas none had Ն two. 17 Hence, there is a possibility that using a threshold of Ն one will incorrectly assign a patient to a poor prognostic group, but this must be balanced against the risk of wrongly assigning a patient to a good prognostic group if a cutoff of Ն two is used, and a patient has only one CTC detected.
Presence of CTCs was clearly associated with increasing tumor burden and grade. Despite this, CTCs were independently associated with PFS and OS in multivariate analysis, with a 3.3-fold increase risk of progression and 3.7-fold increase risk of death in those patients with Ն one CTC at baseline. The only other factor to retain significance was grade, and this was mainly because of the higher risk associated with grade 3 tumors. However, in clinical practice, high-grade tumors represent the minority of NETs and are usually treated at diagnosis with chemotherapy. Therefore, it is important to understand the implications of CTCs in grade 1 and 2 tumors, which constitute the majority. In both groups, presence of CTCs was still able to define a poor prognostic group for PFS and OS in univariate analysis. However, a longer period of follow-up and more events are needed to produce more accurate estimates of the effect sizes with regard to OS, particularly in patients with grade 1 disease.
Grade is usually assigned on a baseline biopsy that may not be representative of a heterogeneous tumor and might have been performed years before treatment decisions are made. CTCs, on the contrary, provide information about the tumor and prognosis at the time a management decision needs to be made and seem to provide useful information over and above that provided by grade alone. The only other prognostic marker widely used in NETs is CgA, an acid glycoprotein and component of dense core secretory granules in neuroendocrine cells. The absolute CgA levels measured in serum or plasma vary depending on the assay used, and levels can be elevated in both benign and malignant conditions. Therefore, CgA is not a specific marker for NETs. 26 As a prognostic marker, the results in clinical studies are conflicting, and there are few prospective studies. 7, 8 In the PROMID study of octreotide LAR in metastatic midgut NETs, CgA levels above the ULN were not prognostic for time to progression or tumor-related death, 27 whereas in studies of everolimus, elevation of CgA Ͼ 2ϫ ULN has been associated with reduced PFS.
19 Our prospective data do support CgA as a prognostic marker, but as a dichotomous variable Ͼ 2ϫ ULN, it is a poor discriminator in univariate analysis and not significant in multivariate analysis.
There are some limitations to our study. First, we have looked at a heterogeneous population in terms of primary site, in which midgut tumors were highly represented, and few data were available for bronchial, hindgut, and unknown primary. In the limited number that were included, CTCs were detected, and these subgroups will require further analysis in multicenter prospective studies. Second, although the follow-up for PFS was sufficient, the follow-up time for OS was relatively short, and median survival was not reached in patients with grade 1 and 2 tumors. Therefore, a further period of follow-up is required to define the role of CTCs with respect to OS.
In the past few years, there have significant advances in the treatment of NETs with the approval of both sunitinib and everolimus in pancreatic NETs. Because of the indolent nature of some NETs, many trials mandate documented progression within 12 months, which may require a period of observation off treatment, which is not always appropriate or acceptable. The ability of CTCs to define a population of patients with well-differentiated tumors that are likely to progress may provide a means of stratifying a high-risk group for early intervention. The evaluation of CTC-based clinical decision making is being addressed in ongoing trials in other cancers (such as SWOG [Southwest Oncology Group] S0500) and requires assessment in NETs.
The identification of CTCs in NETs also presents a number of other opportunities. Their role as predictive biomarkers of response to treatment needs to be explored; several NET trials have incorporated CTCs as an exploratory end point. Moreover, the capacity to capture and characterize CTCs may further facilitate the stratification of patients for therapy. [28] [29] [30] Outstanding challenges for cancer therapy include tumor heterogeneity and the emergence of drug resistance; the ability to readily sample tumor cells in the form of CTCs during the course of the disease may help inform treatment choices. Therapeutic targets including human epidermal growth factor receptor 2 and epidermal growth factor receptor have been identified in CTCs, and recent studies have demonstrated the ability to undertake single-cell sequencing.
31-33 New methods to isolate CTCs for molecular characterization are being developed, and these innovations present exciting opportunities to interrogate CTCs as an alternative to invasive biopsies. 34, 35 In summary, this is the first study to our knowledge in NETs demonstrating the prognostic significance of CTCs as detected by the CellSearch system. The findings expand on those in other epithelial cancers and open the way for further evaluation of CTCs as liquid biopsies in this tumor type.
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